Viromer® next generation transfection reagents

Viromer® are strong and powerful, polymer based transfection reagents, that provide excellent performance in standard and even in challenging primary and suspension cells.

About Viromer®

Please be informed:

BioNTech Protein Therapeutics GmbH, a wholly owned subsidiary of BioNTech SE, on January 6th 2020 acquired all assets, employees and proprietary know how of Lipocalyx GmbH.

Viromer transfection reagents for gene knock-down and knock-out
Viromer Transfection reagents for overexpression experiments via plasmid or mRNA

Excellent Performance
based on high-tech polymers

Easy to use
optimization guide

Use our optimization guide to find the best conditions for your special cells and target

Compatible with primary and suspension cells

Due to an active escape from the endosome Viromer® is suitable for hard-to-transfect cells

Highly Efficient
and low-toxic

Viromer® complexes are non-charged, gentle on cells, and compatible with serum and antibiotics.

Learn more about VIROMER®

Product overview

What makes Viromer® so efficient?

Watch Our Video

Take two minutes to discover the story behind the Viromer® transfection reagents. Inspired by the machinery of the Influenza virus to penetrate cells and actively escape from the endosome, at Lipocalyx, we have been using this as a blueprint to develop a functional copy of the virus based on high-tech polymers.

The 4 color-named Viromer® and related customized reagents are the result of this work. This palette permits to provide the most appropriate chemistry to deliver RNA or DNA in each specific cell line you commonly use in research labs. And the story goes on with in vivo applications…

picture of the opened Viromer® Transfection Factbook

Download Factbook

“Facts” are better than words. This booklet compiles the most impressive data we have collected so far from the Viromer® users’ community. You will find as well the full list of Viromer® reagents and some more information about the technology, ordering and technical support, and our international distributors’ network. We send willingly printed versions on request.

Viromer® Product Overview

in vitro transfection

Choose between liquid and lyophilized formats for siRNA/miRNA or pDNA/mRNA transfections

CRISPR RNP delivery

Cas9 protein and gRNA complex (RNP) has been proven to be more effective in gene editing

pharmaceutical applications

Enabling delivery of mRNA, siRNA or Cas9 into target tissues and cells for genetic medicines

Learn more about Viromer®

Viromer® Cell Transfection Database

Viromer® Transfection cell database

Use our enormous cell database to figure out the Viromer® that you will need for your special applications. Go through a list of around 150 different cell types – from adherent to suspension and primary cells to classical cell lines. See transfection efficiencies, have a deeper look into customer data, experimental conditions or provided hints and tipps. Read cell type specific publications and inform yourself about how Viromer® can support your research.

Search easier: sort the alphabetical cell database for adherent, suspension, primary or stem cells. Simply use the main navigation in the header.

Use Cases: How Viromer® helps

Viromer® in
immunology research

MPS cells are known to be difficult targets. They are likely very efficient for scanning the extra-cellular environment and uptaking materials but have a strong ability of self-defense.

Viromer® in
oncology research

As immortalized and transformed cells, the fate of cancer cells into a defined organ and their potential to spread to other tissues are typically considered in a context of gene regulation. Transfection is therefore a powerful tool…

Viromer® in
myology / cardio-vascular research

Covering the study of muscle physiology, myogenesis, muscular and neuromuscular diseases, injuries, aging, sport-induced damages, it involves a very active work at the bench to better understand the …

Viromer® in
metabolic research

Obesity and the related diseases had been found to be the most important public health problems of the 21st century. The in vitro transfection of the related cells is an unevitable necessity in research to understand the molecular mechanisms behind.

Viromer® in
neurobiology research

One challenge for neurobiologists is to manipulate cell or animal models in the lab, for which transfection has notably a strong limitation. Primary neurons and neural stem cells are for instance not easily amenable to transfection mediated by chemical reagents because of …

Viromer® in
mRNA transfection

Transfecting cells with mRNA sequences rather than plasmid DNA constructs gives a great chance to significantly increase transient protein expression levels in a majority of cell types, and offers a unique alternative for challenging cells.

What is transfection?

Transfection is a Challenge

Transfection is a powerful method to introduce foreign DNA or RNA into eukaryotic cells. Delivery of nucleic acids into cells enables exploration of gene function and regulation, analysis of cellular pathways and signal transduction in cells, tissues and organisms.

There are various transfection techniques developed: viral transduction, mechanical methods (such as electroporation or microinjection), chemical methods (such as calcium phosphate, polymers or lipofection) and hybrid methods (such as magnetofection). Nevertheless, a successful transfection of certain cells remains a challenging task.

A new generation of
transfection reagents

Lipocalyx develops and manufactures the new generation proprietary synthetic transfection reagents Viromer® based on high-tech polymers that combine the best features of chemical transfection and mimick the natural ptake of the influenza virus to enable an outstanding transfer of RNAs and DNA into various hard-to-transfect cells, including primary cells, stem cells or suspension cells. Viromer® are compatible as well with many classical immortalized cell lines, including cancer cell lines widely used in cell biology. They are highly efficient, easy to use and low-toxic transfection reagents.

Meet us at Conferences and Events

RNA Therapeutics

February 21 – 22nd, 2018

Holiday Inn Kensington Forum

London, United Kingdom

by EBD Group

March 11 – 14th, 201

Amsterdam RAI Convention Center

Amsterdam, Netherlands

Annual Meeting 2018

April 14-18th, 2018

McCormick Place North / South

Chicago, USA


May 4-8th, 2018

Austin Convention Center

Austin, USA